PDF(Pubmed)
Abstract：
UNASSIGNED: Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a distinct clinicopathological entity with an aggressive clinical course. Additionally, SMARCA4/BRG1 deficiency can be observed in a few patients with non-small cell lung cancer (NSCLC). We aimed to compare the clinicopathological, immunohistochemical and prognostic features of SMARCA4-deficient NSCLC (SMARCA4-dNSCLC) with those of thoracic SMARCA4-UT.
UNASSIGNED: Patients with BRG1-deficient tumors in the lung or thorax were enrolled in the study from the Department of Pathology of West China Hospital, Sichuan University, from January 2014 to June 2022. We retrospectively collected the clinicopathological and immunohistochemical features and outcomes of these patients.
UNASSIGNED: Seventy-two patients had tumors in the lung or thorax with BRG1-deficient expression, including 52 patients with SMARCA4-dNSCLC and 20 patients with thoracic SMARCA4-UT. Among the patients with SMARCA4-dNSCLC, 98.1% were male, 85.7% were smokers, and 79.5% (35/44) had tumor-node-metas-tasis (TNM) III-IV tumors. Among the patients with thoracic SMARCA4-UT, all were males who smoked, and 93.75% (15/16) had TNM III-IV tumors. Pure solid architecture and necrosis were the predominant pathological features. Rhabdoid morphology was observed in some SMARCA4-dNSCLCs (10/52, 19.2%) and thoracic SMARCA4-UTs (11/20, 55%). In most patients with thoracic SMARCA4-UT, the tumors exhibited scattered weak expression or negative expression of epithelial markers, and positive expression of CD34 and Syn. Overall survival (OS) and progression-free survival (PFS) were not significantly different between patients with SMARCA4-dNSCLC and patients with thoracic SMARCA4-UT (p = 0.63 and p = 0.20, respectively).
UNASSIGNED: Thoracic SMARCA4-DTs include SMARCA4-dNSCLC and thoracic SMARCA4-UT. Both have overlapping clinicopathological features and poor prognosis. We hypothesize that thoracic SMARCA4-UT may be the undifferentiated or dedifferentiated form of SMARCA4-dNSCLC. However, further studies with larger cohorts and longer follow-up periods are needed.
UNASSIGNED: Patients with BRG1-deficient tumors in the lung or thorax were enrolled in the study from the Department of Pathology of West China Hospital, Sichuan University, from January 2014 to June 2022. We retrospectively collected the clinicopathological and immunohistochemical features and outcomes of these patients.
UNASSIGNED: Seventy-two patients had tumors in the lung or thorax with BRG1-deficient expression, including 52 patients with SMARCA4-dNSCLC and 20 patients with thoracic SMARCA4-UT. Among the patients with SMARCA4-dNSCLC, 98.1% were male, 85.7% were smokers, and 79.5% (35/44) had tumor-node-metas-tasis (TNM) III-IV tumors. Among the patients with thoracic SMARCA4-UT, all were males who smoked, and 93.75% (15/16) had TNM III-IV tumors. Pure solid architecture and necrosis were the predominant pathological features. Rhabdoid morphology was observed in some SMARCA4-dNSCLCs (10/52, 19.2%) and thoracic SMARCA4-UTs (11/20, 55%). In most patients with thoracic SMARCA4-UT, the tumors exhibited scattered weak expression or negative expression of epithelial markers, and positive expression of CD34 and Syn. Overall survival (OS) and progression-free survival (PFS) were not significantly different between patients with SMARCA4-dNSCLC and patients with thoracic SMARCA4-UT (p = 0.63 and p = 0.20, respectively).
UNASSIGNED: Thoracic SMARCA4-DTs include SMARCA4-dNSCLC and thoracic SMARCA4-UT. Both have overlapping clinicopathological features and poor prognosis. We hypothesize that thoracic SMARCA4-UT may be the undifferentiated or dedifferentiated form of SMARCA4-dNSCLC. However, further studies with larger cohorts and longer follow-up periods are needed.
摘要：
■胸部SMARCA4缺陷型未分化肿瘤(SMARCA4-UT)是一种独特的临床病理实体，具有侵袭性临床病程。此外,在少数非小细胞肺癌（NSCLC）患者中可以观察到SMARCA4/BRG1缺乏。我们的目的是比较临床病理，SMARCA4缺陷型NSCLC（SMARCA4-dNSCLC）与胸段SMARCA4-UT的免疫组织化学和预后特征。
■来自华西医院病理科的肺部或胸部BRG1缺陷型肿瘤患者被纳入研究，四川大学,2014年1月至2022年6月。我们回顾性收集这些患者的临床病理和免疫组织化学特征以及结果。
■72例患者肺部或胸部有BRG1缺失表达的肿瘤，包括52例SMARCA4-dNSCLC患者和20例胸部SMARCA4-UT患者。在SMARCA4-dNSCLC患者中，98.1%为男性，85.7%是吸烟者，79.5%(35/44)患有肿瘤淋巴结转移(TNM)III-IV型肿瘤。在胸部SMARCA4-UT患者中，都是吸烟的男性，93.75％（15/16）患有TNMIII-IV肿瘤。纯实体结构和坏死是主要的病理特征。在一些SMARCA4-dNSCLCs（10/52，19.2％）和胸部SMARCA4-UT（11/20，55％）中观察到横纹肌形态。在大多数胸部SMARCA4-UT患者中，肿瘤表现为上皮标志物零散弱表达或阴性表达，CD34和Syn的阳性表达。SMARCA4-dNSCLC患者和胸段SMARCA4-UT患者的总生存期（OS）和无进展生存期（PFS）没有显着差异（分别为p=0.63和p=0.20）。
■胸部SMARCA4-DTs包括SMARCA4-dNSCLC和胸部SMARCA4-UT。两者具有重叠的临床病理特征和不良预后。我们假设胸部SMARCA4-UT可能是SMARCA4-dNSCLC的未分化或去分化形式。然而,需要进一步研究更大的队列和更长的随访时间.
■来自华西医院病理科的肺部或胸部BRG1缺陷型肿瘤患者被纳入研究，四川大学,2014年1月至2022年6月。我们回顾性收集这些患者的临床病理和免疫组织化学特征以及结果。
■72例患者肺部或胸部有BRG1缺失表达的肿瘤，包括52例SMARCA4-dNSCLC患者和20例胸部SMARCA4-UT患者。在SMARCA4-dNSCLC患者中，98.1%为男性，85.7%是吸烟者，79.5%(35/44)患有肿瘤淋巴结转移(TNM)III-IV型肿瘤。在胸部SMARCA4-UT患者中，都是吸烟的男性，93.75％（15/16）患有TNMIII-IV肿瘤。纯实体结构和坏死是主要的病理特征。在一些SMARCA4-dNSCLCs（10/52，19.2％）和胸部SMARCA4-UT（11/20，55％）中观察到横纹肌形态。在大多数胸部SMARCA4-UT患者中，肿瘤表现为上皮标志物零散弱表达或阴性表达，CD34和Syn的阳性表达。SMARCA4-dNSCLC患者和胸段SMARCA4-UT患者的总生存期（OS）和无进展生存期（PFS）没有显着差异（分别为p=0.63和p=0.20）。
■胸部SMARCA4-DTs包括SMARCA4-dNSCLC和胸部SMARCA4-UT。两者具有重叠的临床病理特征和不良预后。我们假设胸部SMARCA4-UT可能是SMARCA4-dNSCLC的未分化或去分化形式。然而,需要进一步研究更大的队列和更长的随访时间.
